SCHEDULE 13G/A 0000902664-24-006530 0001633313 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 12/31/2024 0000879407 Arrowhead Pharmaceuticals, Inc. 04280A100 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 Rule 13d-1(b) Avoro Capital Advisors LLC b DE 12028552.00 0.00 12028552.00 0.00 12028552.00 N 9.6 IA OO Includes 917,441 shares of Common Stock issuable upon exercise of warrants Behzad Aghazadeh b X1 12028552.00 0.00 12028552.00 0.00 12028552.00 N 9.6 HC IN Includes 917,441 shares of Common Stock issuable upon exercise of warrants Arrowhead Pharmaceuticals, Inc. 177 E Colorado Blvd, Suite 700, Pasadena CA 91105 This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired the shares of common stock, par value $0.001 per share ("Common Stock") and the shares of Common Stock underlying warrants of Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the "Company"), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012. Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 124,434,442 shares of Common Stock outstanding as of November 22, 2024 as reported in the Company's Prospectus filed pursuant to Rule 424(b)(7) , filed with the Securities and Exchange Commission on December 20, 2024, and assumes the exercise of warrants reported herein. 9.6 The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Avoro Capital Advisors LLC /s/ Scott Epstein 02/14/2025 Behzad Aghazadeh /s/ Behzad Aghazadeh 02/14/2025